Insulin glargine versus NPH insulin therapy in Asian Type 2 diabetes patients

What Was Tested

Researchers studied Insulin Glargine and NPH Insulin (isophane) in this randomized controlled trial publication.

This study investigated the effect of insulin glargine (LANTUS) versus NPH insulin on metabolic control and safety in Asian patients with Type 2 diabetes, inadequately controlled on oral hypoglycemic agents (OHAs).

Who Took Part

The study group was 443 patients.

By PubMed's age tags, the people studied were middle-aged adults, both men and women.

How the Study Was Run

The design is described as randomized, open-label and parallel-group.

Random assignment meant chance, not the researchers, decided who got Insulin Glargine and who got the comparison, which limits bias.

Being open-label, the Insulin Glargine study did not mask who received what.

The Insulin Glargine group and the comparison group ran side by side rather than switching.

What Was Measured

The subject headings attached to it are Asian People, Blood Glucose, Diabetes Mellitus, Type 2, Glycated Hemoglobin, Hypoglycemia, Hypoglycemic Agents and Insulin.

What This Means in Plain Language

The paper is a randomized, open-label and parallel-group study of Insulin Glargine and NPH Insulin (isophane) in 443 patients.

With several hundred people or more, it is a fairly large study for this kind of research.

Its findings take up roughly 7 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2007 (Diabetes research and clinical practice), a journal based in Ireland.

More context: the Insulin Glargine compound page and the NPH Insulin (isophane) compound page.